LNAI
Lunai Bioworks Inc. Common Stock (LNAI)
Healthcare • NASDAQ • $0.33-0.90%
- Symbol
- LNAI
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $0.33
- Daily Change
- -0.90%
- Market Cap
- $11.97M
- Trailing P/E
- N/A
- Forward P/E
- N/A
- 52W High
- $5.50
- 52W Low
- $0.15
- Analyst Target
- N/A
- Dividend Yield
- N/A
- Beta
- 0.33
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients. The company was formerly known as Renovaro Inc. and changed its name to Lunai Bioworks Inc. in August 2025. Lunai Bioworks In…
Company websiteResearch LNAI on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.